key: cord-0855125-cvpxd077 authors: Das, S.; Tumpa, N. I.; Khan, A. A.; Hoque, M. M.; Hoque, M. E.; Jahan, S.; Ahmed, K. F.; Biswas, R. S. R. title: Relation of vaccination with severity, oxygen requirement and outcome of COVID-19 infection in Chattogram, Bangladesh date: 2021-06-04 journal: nan DOI: 10.1101/2021.06.03.21257996 sha: 1e58bf6df9fc6717a079b65ab10be0d040bae8ef doc_id: 855125 cord_uid: cvpxd077 Introduction: Peoples all around the world are waiting for vaccination against COVID 19 infection. In Bangladesh, Astra Zeneca (AZ) vaccine was provided, but patients had infections of SARS COV 2 even after vaccination. We focused on observing the severity, oxygen requirement and outcome of the COVID-19 infected patients who took the first dose or completed the immunization regimen. Methods: This is an observational study done among 174 COVID 19 patients from three COVID 19 dedicated hospitals of Chattogram, Bangladesh, who took AZ vaccines 1st dose or completed the schedule. All patients were Real-Time Reverse Transcription Polymerase Chain Reaction (rRT PCR) positive for COVID 19. Patients were enrolled after receiving written informed consent. Suspected cases or unwilling patients were excluded from the study. Ethical approval was granted by the CMOSH ERB. SPSS 20 was used to analyze the information gathered. Results: Among 174 vaccinated patients, 55(31.61%) completed the vaccination schedule, and 119(68.39%) took their 1st dose of the COVID 19 vaccine. Gender distributions revealed 67(38.5%) female and 107(61.5%) male got the vaccine, and 55 patients completed the full two doses, and 119 patients took the 1st dose. Most of the patients were 40 years and above. In the completed vaccination group, 33(60.0%) out of 55 in and in the first dose vaccinated group, 75(63.0%) out of 119 had a mild COVID 19, and severe and critical cases were found very minimum. Among the patients who have completed the vaccination, 32(58.2%) needed no oxygen, and who was given the first dose, 78(65%) needed no oxygen. No death occurred who completed the vaccine, and 3(2.5%) patients died who took 1st dose of the vaccine. Conclusion: Vaccine provided in Bangladesh to the people so far seems safe and effective. Severe and critical COVID 19 is low, and the need for oxygen to admitted patients is less, and the death rate is minimal. health emergency with significant social and economic disruptions and devastating health consequences. All over the world, scientists are developing vaccines. Some are already at the community level, and some are in different trial phases. The rapid development of vaccines is imperative.1 Different countries all over the world are using different vaccines from different sources. Those are showing different types of effectiveness. The immune response to many other vaccines has been shown to decrease with increasing age.2 In Bangladesh, vaccines were provided to most people who were more than 40 years early and all health care workers of different ages. Thus, the testing of SARS-CoV-2 vaccine candidates in older populations is of paramount importance since these persons account for the most serious COVID 19 cases and associated deaths.3,4 SARS-CoV-2 A study done among Health Care Workers in California5 found the rarity of positive test results 14 days after administration of the second dose of vaccine is encouraging and suggests that the efficacy of these vaccines is maintained outside the trial setting. These data underscore the critical importance of continued public health mitigation measures (masking, physical distancing, daily symptom screening, and regular testing), even in environments with a high incidence of vaccination, until herd immunity is reached at large. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) All patients got AZ vaccines 1st dose or completed the schedule earlier. Patients visiting the COVID-19 outdoor for testing were asked if they had received the vaccine, and if they had, they were tested for COVID-19 rRT-PCR. Again those patients who admitted to the hospital directly were asked whether they got vaccines. If the answer was yes, they were also enrolled in the study and followed up till discharge or death. All data were collected after written informed consent from the patients or the corresponding guardians, and ethical permission was obtained from the Chattagram Maa-Shishu O General Hospital's ERB. Patients were categorized as mild, moderate, severe and critical to define the severity according to Bangladesh's national guideline of COVID-19 management. Also, they were divided into two groups that got oxygen in any form. Suspected cases or those who were unwilling to be included in the study were excluded. After data collection, those were analyzed by SPSS-20(IBM SPSS-Armonk, NY, USA). . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 1) . Most of the patients are 40 years and above( Table 2) Among all 33 (60.0%) out of 55 in the completed vaccination group and 75(63.0%) out of 119 in the first dose vaccinated group were having a mild form of COVID-19 and severe and critical cases were minimum (Table 3) . Who finished the immunization regimen, 32 (58.2%) of them did not require oxygen, while 78 (65%) of patients who received only the first dose did not require oxygen (Table 4 ) No death occurred who completed the vaccine, and 3 (2.5%) patients died who took the 1 st dose of vaccine (Table 5) . . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 4, 2021. ; https://doi.org/10.1101/2021.06.03.21257996 doi: medRxiv preprint The emergence in December 2019 of a novel coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had devastating consequences globally.6 Control measures such as using masks, physical distancing, testing of exposed or symptomatic persons, contact tracing, and isolation have helped limit the transmission where they have been rigorously applied. However, these actions have been variably implemented and have proved insufficient in impeding the spread of COVID-19, the disease caused by SARS-CoV-2. Vaccines are needed to reduce the morbidity and mortality associated with COVID-19, and multiple vaccine platforms have been involved in the rapid development of vaccine candidates.7 In the present study, more male was vaccinated, and most of them were above 40 years. Male Overall, these findings show that in a small group of participants, the severity of COVID-19 was mainly mild or moderate, oxygen need among hospitalized patients was less, and the death toll was minimum provided with the AZ vaccine used in Bangladesh. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Pearson Chi-Square value 11.63, p=0.001 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 4, 2021. ; https://doi.org/10.1101/2021.06.03.21257996 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 4, 2021. ; https://doi.org/10.1101/2021.06.03.21257996 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 4, 2021. ; https://doi.org/10.1101/2021.06.03.21257996 doi: medRxiv preprint World Health Organization. Draft landscape of COVID 19-19 candidate vaccines Immune senescence and vaccination in the elderly Factors associated with COVID 19-19-related death using OpenSAFELY CDC COVID 19-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID 19-19) -United States SARS-CoV-2 infection after vaccination in health care workers in California An mRNA vaccine against SARS-CoV-2 -preliminary report Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine Barua PK Relation of Age and Sex Variations with Outcome of COVID 19-19 Patients : Three Months Data from A COVID 19 Dedicated Hospital from Bangladesh Efficacy and Safety of the mRNA-1273